Adaptimmune Therapeutics Banner Image

Adaptimmune Therapeutics has reached its limit for free report views

Work for Adaptimmune Therapeutics? Upgrade Your Profile and unlock all your annual reports.

Adaptimmune Therapeutics

  • Ticker ADAP
    Exchange NASDAQ More
  • Industry Medical Appliances & Equipment More
  • Sector Healthcare More
Adaptimmune Therapeutics Logo Image
  • 201-500 Employees
  • Based in Abingdon, England
Adaptimmune, a leader in T-cell therapy, is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary SPEAR T-cell receptor platform to treat solid tumors, which has the potential to transform the treatment of cancer. Their proprietary SPEAR T-cell platform has generated a strong pipeline of affinity-enhanced T-cell therapiesMore, with multiple INDs open. They use these therapies to harness the body's own immune system to find and destroy diseased cells. Their SPEAR TCR therapies offer promise to patients that often have no other options. They are working hard to make that promise a reality.
4.8 / 5.0 (198)

Adaptimmune Therapeutics reports have an aggregate usefulness score of 4.8 based on 198 reviews.

Adaptimmune Therapeutics

Most Recent Annual Report

Adaptimmune Therapeutics
MOST RECENT 2022 Annual Report and Form 10K

Report Locked. Adaptimmune Therapeutics has reached its limit for free report views.

Older/Archived Annual Reports

Adaptimmune Therapeutics Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!